Insulin Glargine: Nursing Drug Guide, Hypoglycemia & NCLEX Review
Once-daily basal insulin with a flat, prolonged glucose-lowering profile — but the bedside danger is delayed hypoglycemia from wrong product or strength, duplicate basal coverage, meal or activity mismatch, and giving a dose during an untreated low.
Hypoglycemia is the most common adverse reaction with insulin glargine and may be life-threatening. It is contraindicated during hypoglycemia. Never share pens or needles between patients. Verify the insulin name, concentration (U-100 vs U-300), and dose before every injection — accidental mix-ups among insulin products are reported. Increased glucose monitoring is required with dose changes, meal or activity changes, interacting drugs, renal or hepatic impairment, and hypoglycemia unawareness. Treat hypoglycemia before administering any insulin dose, document product and site, and escalate severe or recurrent lows per protocol.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Insulin glargine is a once-daily basal insulin — not a correction or meal-time insulin. Before every dose, confirm blood glucose is safe, verify the correct product and concentration (U-100 vs U-300), and ensure the patient is not receiving duplicate basal insulin from another order or home supply. Because hypoglycemia can occur hours later, teach patients to recognize lows, carry fast-acting carbohydrate, and never skip glucose checks after dose changes.
Most common brand names
Insulin glargine is a long-acting basal insulin analog available under multiple brand and biosimilar names. Always match the specific product, concentration, and delivery device on the MAR to the vial or pen in hand.
Common brands: Lantus and Lantus SoloStar; Basaglar KwikPen and Basaglar Tempo Pen; Toujeo and Toujeo Max (300 units/mL); Semglee; Rezvoglar KwikPen. Combination product: Soliqua 100/33 (insulin glargine plus lixisenatide). Biosimilar suffixes include insulin glargine-yfgn and insulin glargine-aglr. Institutional formularies and device types may vary.
Why we give it — Indications
Insulin glargine provides basal insulin replacement in patients with diabetes mellitus. It is not for acute hyperglycemic crises and must be paired with short-acting or rapid-acting insulin in type 1 diabetes per labeling.
| Use | Detail |
|---|---|
| Type 1 diabetes mellitus | Basal insulin component of intensive insulin therapy. In type 1 diabetes, insulin glargine must be used concomitantly with short-acting, premeal insulin to cover prandial glucose. |
| Type 2 diabetes mellitus | Basal insulin when glycemic control is not achieved with oral agents and lifestyle measures. Often added when type 2 diabetes remains above goal despite other therapy. |
On a small screen, swipe or scroll sideways to see the full table.
Not an indication: Insulin glargine is not recommended for the treatment of diabetic ketoacidosis (DKA).
How it works
Insulin glargine is a long-acting human insulin analog. Its primary activity is regulation of glucose metabolism: insulin stimulates peripheral glucose uptake (especially skeletal muscle and fat) and inhibits hepatic glucose production. It also inhibits lipolysis and proteolysis and enhances protein synthesis. The modified amino acid sequence produces a relatively flat, prolonged absorption profile without a pronounced peak compared with NPH insulin — which is why nurses must not treat it like a meal-time or correction insulin.
Dosing overview
Dosing is individualized based on metabolic needs, blood glucose monitoring, glycemic goals, diabetes type, and prior insulin use. Verify every order against current prescribing information, renal/hepatic status, and institutional protocol.
Switching insulins: When changing to insulin glargine from other basal insulins, labeling provides conversion guidance (for example, from once-daily Toujeo U-300 to Lantus U-100: start Lantus at 80% of the Toujeo dose; from once-daily NPH: same units; from twice-daily NPH: 80% of total NPH dose). Closely monitor glucose during the first weeks after any switch. Patients on oral agents such as metformin may need oral dose adjustment when basal insulin is added.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses. Contact prescriber or pharmacist for guidance per institutional protocol.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Gradual after subcutaneous injection; slower, prolonged absorption vs NPH | Do not expect immediate correction of high glucose — this is basal coverage, not a stat insulin |
| Peak | No pronounced peak vs NPH; relatively constant concentration over 24 hours | Hypoglycemia risk can persist for many hours — reassess glucose on an ongoing schedule, not only immediately after injection |
| Duration | Median end of pharmacologic effect ~24 hours (range 10.8 to >24 hours) in type 1 study vs NPH ~14.5 hours | Once-daily dosing at the same time each day; missed meals or extra activity later in the day can still trigger delayed hypoglycemia |
| Half-life | Not specified in the reviewed prescribing information as a single nursing summary value | Effect varies between and within patients; injection site, blood supply, and temperature can alter action |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Check most recent blood glucose and trend before every dose — do not administer during hypoglycemia
- Verify correct patient, drug name, concentration (U-100 vs U-300), dose in units, route, and scheduled time; perform independent double check per high-alert policy
- Review meal plan, NPO status, activity level, renal/hepatic function, and interacting drugs (especially antidiabetic agents, corticosteroids, beta-blockers, and alcohol)
Contraindications
- During episodes of hypoglycemia
- Hypersensitivity to insulin glargine or any excipient in the specific product
- Do not use during untreated hypoglycemia — treat the low first, then clarify next basal dose with prescriber/pharmacist
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Other antidiabetic agents, ACE inhibitors, ARBs, salicylates, SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors | May increase hypoglycemia risk | Increase glucose monitoring; anticipate need for insulin dose reduction per prescriber/pharmacy when these are added or dose-escalated |
| Corticosteroids, thiazide diuretics, sympathomimetics, thyroid hormones, protease inhibitors | May decrease blood-glucose-lowering effect | Monitor for worsening hyperglycemia; notify prescriber if glucose trend rises after steroid bursts or new interacting therapy |
| Beta-blockers, clonidine, alcohol | May increase or decrease glucose effect; beta-blockers may blunt hypoglycemia symptoms | Increase monitoring frequency; teach that sweating and tremor may be masked — rely on glucose checks, not symptoms alone |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Subcutaneous only — abdominal area, thigh, or deltoid. Rotate injection sites within the same region. Do not administer IV, IM, or via insulin pump unless a specific product and protocol explicitly support it (standard insulin glargine labeling is for subcutaneous use).
- Administer once daily at any time of day but at the same time every day
- Do not dilute or mix insulin glargine with any other insulin or solution — give as a separate injection
- Never share pens, syringes, or needles between patients, even if the needle is changed
Accidental mix-ups among insulin products and strengths are reported. Instruct patients to check the label before every injection. Repeated injections into lipodystrophy or localized cutaneous amyloidosis can cause hyperglycemia; changing to an unaffected site may cause hypoglycemia — monitor glucose closely after site changes. Use proper subcutaneous injection technique and document site rotation.
Expected therapeutic response
- Improved fasting and between-meal glucose when basal insulin was the gap in the regimen
- Gradual improvement in glycated hemoglobin (HbA1c) over weeks — not within minutes of a single dose
- Stable overnight glucose when dose, meals, and activity are consistent — persistent overnight lows or hyperglycemia symptoms warrant prescriber review
Red flags — Stop and act
Escalate immediately for signs of severe hypoglycemia, hypersensitivity, or metabolic complications. Basal insulin errors may present hours after administration.
- Blood glucose below institutional hypoglycemia threshold, especially with altered mental status, seizure, or need for assistance
- Diaphoresis, tremor, confusion with low sugar, dizziness, or hunger not corrected with fast-acting carbohydrate
- Generalized allergic reaction or anaphylaxis (rash, angioedema, bronchospasm, hypotension) — discontinue insulin and treat per emergency protocol
- Persistent hyperglycemia with ketosis symptoms after suspected wrong-insulin or wrong-dose error — evaluate for DKA pathway per protocol
- Signs of hypokalemia on monitoring (muscle weakness, arrhythmia) in at-risk patients receiving insulin therapy
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Hypoglycemia | Most common adverse reaction; may be severe or life-threatening | Treat low glucose immediately; hold subsequent insulin until glucose safe and prescriber advises; increase monitoring after dose changes |
| Injection site reactions, lipodystrophy | Common; lipoatrophy or lipohypertrophy reported | Rotate sites within region; avoid scarred or lumpy areas; monitor glucose when changing sites |
| Weight gain, peripheral edema | Reported in clinical trials (e.g., edema peripheral ~20% in 5-year type 2 study) | Document trend; reinforce diet and activity teaching; notify prescriber if rapid weight gain or heart failure symptoms with TZD co-therapy |
| Allergic reactions, pruritus, rash | Reported; anaphylaxis possible | Stop insulin glargine for systemic hypersensitivity; treat per protocol; never rechallenge if contraindicated |
| Hypokalemia | Serious; all insulins can shift potassium intracellularly | Monitor potassium in at-risk patients; treat per prescriber if clinically significant on basic metabolic panel |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Excess insulin glargine causes hypoglycemia ranging from mild to life-threatening. Because of its long duration, prolonged monitoring is required even after initial treatment.
Early signs
- Adrenergic symptoms: sweating, tremor, palpitations, hunger (hypoglycemia symptoms)
- Neuroglycopenic symptoms: confusion, difficulty concentrating, seizure, loss of consciousness
- Symptoms may be blunted in patients taking beta-blockers or with hypoglycemia unawareness
Antidote / reversal
No specific antidote. Mild hypoglycemia: oral fast-acting carbohydrate. Severe hypoglycemia with altered consciousness: glucagon for emergency use or intravenous glucose per protocol, then continued observation because hypoglycemia may recur. Lower insulin dosage and adjust meals or activity as directed. Contact local poison control or medical toxicology services per facility protocol for severe or refractory cases.
Look-alike / sound-alike and error prevention
- Insulin glargine vs rapid-acting insulins (e.g., insulin lispro, insulin aspart) — different onset and purpose; never substitute at the bedside
- U-100 vs U-300 (Lantus/Basaglar vs Toujeo) — same unit dose does not equal same glucose effect; 300 units/mL pens deliver triple concentration per unit marking
- Brand/biosimilar names (Lantus, Basaglar, Semglee, Rezvoglar) — verify exact product on MAR matches vial or pen label
- Duplicate basal therapy — home glargine plus inpatient basal order, or glargine plus degludec/detemir without intentional switch
- “Units” vs mL — insulin is dosed in units; use insulin syringes or pen devices calibrated in units only
- Shared pen devices — never share, even with needle change; bloodborne pathogen risk per labeling
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Mixing | Do not mix or dilute insulin glargine with any other insulin or solution. |
| Timing | Once daily at the same time each day; not tied to meals like prandial insulin, but meal and activity changes still affect hypoglycemia risk. |
| Storage | Follow product labeling for vial or pen — unrefrigerated in-use pens/vials have defined room-temperature limits; do not freeze. |
| Lab timing | Point-of-care glucose before every dose; HbA1c tracks long-term control; BMP potassium if hypokalemia risk. |
| Commonly missed | Home basal insulin at admission, giving morning instead of bedtime dose without prescriber change, treating hyperglycemia with extra glargine instead of correction insulin. |
| Ask pharmacy when | Insulin switch, unclear U-100 vs U-300 order, pump or enteral feeding changes, recurrent hypoglycemia, or suspected duplicate basal coverage. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Renal or hepatic impairment | Pharmacokinetics not fully studied, but labeling notes higher hypoglycemia risk. Frequent glucose monitoring and conservative dose adjustments are recommended. |
| Older adults | Use conservative initial and maintenance dosing to avoid hypoglycemia. Symptoms may be subtle — prioritize scheduled glucose checks over symptom recognition alone. |
| Hypoglycemia unawareness / beta-blocker use | Reduced adrenergic warning signs; increased monitoring frequency recommended. Teach patients and caregivers to treat based on glucose values. |
| Pregnancy | Published studies have not reported a clear association with adverse developmental outcomes, but poorly controlled diabetes in pregnancy (including gestational diabetes) carries maternal and fetal risk. Use only when clinically needed with close glycemic monitoring. |
| Lactation | Limited data on insulin glargine in human milk; endogenous insulin is present in breast milk. Consider breastfeeding benefits alongside maternal clinical need and potential infant effects — coordinate with prescriber. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Point-of-care blood glucose before each dose and per institutional schedule — increase frequency after dose changes, illness, steroid use, or hypoglycemia events (blood glucose monitoring)
- HbA1c per diabetes care plan to evaluate long-term basal insulin adequacy
- Signs of hypoglycemia, injection-site lipodystrophy, allergic reactions, and hypokalemia in at-risk patients
Document
- Product name, concentration, dose in units, route, site, time, and pre-administration glucose
- Patient response, hypoglycemia treatment given, and prescriber/pharmacy notifications for held or modified doses
- Insulin teaching provided, pen or syringe teach-back, and medication reconciliation at transitions of care
Patient teaching
- This is your basal (background) insulin — take once daily at the same time; it is not your meal-time or correction insulin
- Always check the insulin label and concentration before injecting; do not switch brands or strengths without prescriber guidance
- Recognize hypoglycemia symptoms and carry fast-acting carbohydrate; severe lows may require glucagon or emergency care per local protocol
- Rotate injection sites; report lumps, pits, or recurring redness at injection sites
- Notify your care team before major meal, activity, illness, or steroid changes — basal dose may need adjustment
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Current blood glucose is in the hypoglycemia range or below prescriber/institutional hold parameter
- Patient is having an active hypoglycemic episode — treat first; insulin glargine is contraindicated during hypoglycemia
- Wrong product, concentration (U-100 vs U-300), or dose on MAR does not match available medication
- Duplicate basal insulin suspected (home supply plus inpatient order, or two long-acting insulins without intentional switch)
- Known hypersensitivity to insulin glargine or prior severe allergic reaction to the specific product
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Insulin glargine is a high-stakes basal insulin: the nursing workflow centers on glucose safety, product verification, and coordinated adjustment with the diabetes team when diet, activity, or other medications change.
1. Check-before-you-give protocol
- Right patient, right drug name, right concentration, right dose (units), right route, right time
- Pre-dose blood glucose at or above hold threshold — treat hypoglycemia before any insulin
- Independent double check by second nurse per institutional high-alert insulin policy
- Confirm prandial/correction insulin is a separate product and not mixed with glargine
2. High-alert and safety badge
High-alert medication — extra independent check recommendedInsulin appears on ISMP high-alert medication lists because of the risk of significant patient harm when misused. Treat every glargine dose with the same verification rigor as IV high-alert drugs.
3. Clinical workflow: hold and question rules
- Hold and call pharmacy when MAR shows two basal insulins or home insulin not reconciled at admission
- Question any order to give glargine for acute hyperglycemia without a correction insulin pathway
- Escalate recurrent nocturnal hypoglycemia after recent dose increase — basal may need reduction
4. Critical teach-back questions
- “What type of insulin is glargine?” Long-acting basal insulin taken once daily — not for meals or high glucose corrections.
- “What should you do if your glucose is low before your bedtime dose?” Treat the low first, recheck glucose, and contact your prescriber before taking glargine during hypoglycemia.
5. Care coordination
Prescriber / endocrinology or diabetes team: Dose initiation, insulin switches, sick-day rules, and HbA1c targets.
Pharmacist: Product selection (U-100 vs U-300), biosimilar interchange, interaction review, and pen or syringe supply.
🧠 Quick mental checklist
- Is the pre-dose glucose above the hold threshold?
- Is this the correct insulin product and concentration (U-100 vs U-300)?
- Is the patient on any duplicate basal insulin or unreconciled home supply?
- Has meal, NPO, activity, or steroid status changed since the last dose?
- Did two qualified staff verify the high-alert insulin dose independently?
Insulin Glargine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for insulin glargine safety: priority action after reviewing case tabs, select-all-that-apply cue recognition, glucose trend interpretation, matrix urgency matching, clinical judgment on insulin switches, and documentation cloze. Items focus on hypoglycemia prevention, basal insulin product verification, and evaluating whether glucose trends improve after intervention.
Select a tab to view MAR, labs, Vitals, and nursing note details for this case.
- Insulin glargine (Lantus U-100) 28 units subcutaneous daily at 2100
- Insulin lispro 6 units subcutaneous with meals
- Metformin 1000 mg PO BID
- D5 1/2 NS at 75 mL/h (NPO after midnight for procedure tomorrow)
- 0600 fingerstick glucose: 142 mg/dL
- 1200 fingerstick glucose: 118 mg/dL
- 1700 fingerstick glucose: 96 mg/dL
- 2100 fingerstick glucose (pre-glargine): 58 mg/dL
- HbA1c (admission): 8.4%
- BMP potassium: 4.0 mEq/L
- 2100 — HR 102, BP 148/86, patient diaphoretic, tremulous, reports “shaky and hungry”
- 1800 — HR 78, BP 132/74, alert and oriented
- Weight stable; no fever
- Patient ate only 25% of dinner tray; nurse documented low intake
- Home medication list includes “Lantus 30 units at bedtime” — not yet fully reconciled
- Pharmacy changed inpatient glargine to 28 units yesterday after two overnight lows
- Patient confused glargine SoloStar pen with lispro pen at home last month (education reinforced today)
Answer key & rationale
Frequently asked questions
When should a nurse hold insulin glargine?
Do not give insulin glargine during hypoglycemia — it is contraindicated. Hold and clarify when the glucose is below prescriber or institutional parameters, the order is unclear, the wrong product or strength is available, duplicate basal insulin is suspected, or the patient has a known hypersensitivity to insulin glargine.
Can insulin glargine be mixed with other insulins?
No. Prescribing information states not to dilute or mix insulin glargine with any other insulin or solution. Administer it as a separate subcutaneous injection.
What is the most important nursing risk with insulin glargine?
Hypoglycemia is the most common adverse reaction and may be life-threatening. Risk rises with dose changes, missed meals, increased activity, renal or hepatic impairment, hypoglycemia unawareness, and insulin product or strength errors.
How often should blood glucose be monitored with insulin glargine?
Individualize monitoring per prescriber orders and glycemic goals. Labeling recommends increased glucose monitoring when insulin dosage, meals, activity, or interacting drugs change, and in patients with renal or hepatic impairment or reduced hypoglycemia awareness.
Is insulin glargine used for diabetic ketoacidosis?
No. Insulin glargine is not recommended for the treatment of diabetic ketoacidosis. DKA requires intravenous short-acting insulin and close monitoring per acute-care protocols.
References
-
U.S. National Library of Medicine. LANTUS (insulin glargine) injection — prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6328c99d-d75f-43ef-b19e-7e71f91e57f6
-
Institute for Safe Medication Practices. ISMP List of High-Alert Medications in Acute Care Settings.https://www.ismp.org/sites/default/files/attachments/2017-11/ISMPHighAlertAcuteCare2014.pdf
-
U.S. National Library of Medicine. Insulin glargine — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a600027.html
-
National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management (NG17).https://www.nice.org.uk/guidance/ng17
-
U.S. Food and Drug Administration. Medication Guides — insulin products safety communications.https://www.fda.gov/drugs/drug-safety-and-availability/medication-guides
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.